Key result
Purkinje de-networking showed nonsignificant reductions in mortality and recurrence compared with standard ablation.
Why the study?
Does Purkinje de-networking (PDN) improve acute procedural success and reduce mortality and arrhythmia recurrence compared to trigger-focused or standard catheter ablation in adults with refractory ventricular fibrillation or polymorphic ventricular tachycardia?
Meta-Analysis (n=959)
Does Purkinje de-networking (PDN) improve acute procedural success and reduce mortality and arrhythmia recurrence compared to trigger-focused or standard catheter ablation in adults with refractory ventricular fibrillation or polymorphic ventricular tachycardia?
Purkinje de-networking shows high acute procedural success (83.5%) in refractory VF/PVT, though low-certainty evidence and nonsignificant differences versus standard ablation highlight the need for randomized trials.
Answers are grounded in this paper and cite their sources.
May inform stepwise trigger-first ablation in refractory VF; leaves open need for RCTs to guide PDN adoption.
Ventricular fibrillation (VF) and polymorphic ventricular tachycardia (PVT) are major causes of sudden cardiac death. Although Purkinje-targeted catheter ablation has emerged as a rescue therapy for refractory ventricular arrhythmias, the comparative safety and efficacy of trigger-focused ablation versus Purkinje de-networking (PDN) remain uncertain. To synthesize clinical outcomes for Purkinje-targeted interventions across diverse arrhythmic phenotypes. We searched PubMed, Scopus, Web of Science, Ovid, and CENTRAL for studies enrolling adults with recurrent or refractory ventricular fibrillation (VF) or polymorphic ventricular tachycardia (PVT). We performed pairwise and network meta-analyses using random-effects models. We evaluated the certainty of evidence using GRADE frameworks (PROSPERO: CRD420261423684). We included 22 studies involving 959 patients. Among PDN cohorts, pooled mortality was 13.5% (n = 435; 16 cohorts; 95% CI: 9.0%-20.1%; I2 = 99.28%), acute success was 83.5% (n = 388; 14 cohorts; 95% CI: 78.9%-88.4%; I2 = 34.33%), and VF/PVT recurrence was 18.9% (n = 412; 15 cohorts; 95% CI: 15.7%-22.6%; I2 = 0%). Compared with standard ablation, PDN showed nonsignificant reductions in mortality (RR 0.672, 95% CI: 0.267-1.69; I2 = 0%) and recurrence (RR 0.820, 95% CI: 0.239-2.807; I2 = 70.33%). In the primary network meta-analysis, PDN ranked highest for acute success (SUCRA 86.27%) and freedom from recurrence (77.05%). However, in a sensitivity analysis of comparative trials (9 trials; n = 457), trigger-focused ablation ranked highest for acute success (SUCRA 88.08% vs. 51.52% for PDN). New-onset LBBB occurred in up to 20.8% after substrate-based PDN. In this exploratory network meta-analysis, PDN ranked favorably for acute procedural success and short-term arrhythmia freedom. However, low-certainty evidence, imprecise estimates, and substantial clinical heterogeneity preclude definitive conclusions about its comparative efficacy. Large-scale randomized trials are needed to establish its clinical benefit.
No takes yet. Share an insight, caveat, or question.
El-Shirbiny et al. (2026) conducted a meta-analysis in Recurrent or refractory ventricular fibrillation (VF) or polymorphic ventricular tachycardia (PVT) (n=959). Purkinje de-networking (PDN) catheter ablation vs. Standard or trigger-focused catheter ablation was evaluated on Mortality (along with acute procedural success and VF/PVT recurrence) (RR 0.672, 95% CI 0.267-1.69). Purkinje de-networking showed nonsignificant reductions in mortality and recurrence compared with standard ablation.
Synapse has enriched 10 related papers. Consider them for comparative context: